Table 1.
Patient demographic characteristics
| Characteristic | Overall (n = 296) | Male (n = 161) | Female (n = 135) | P‐value |
|---|---|---|---|---|
| Age (years) | 52.4 ± 12.1 | 52.9 ± 11.5 | 51.9 ± 12.9 | 0.477 |
| HCT type | ||||
| Allogeneic | 296 (100%) | 161 (100%) | 135 (100%) | |
| Days CT to transplant | 26 (11.5) | 27 (13) | 25 (11.2) | 0.608 c |
| Diagnosis, n (%) | ||||
| Non‐Hodgkins lymphoma | 165 (55.7%) | 98 (60.9%) | 67 (49.6%) | 0.394 a |
| Acute lymphocytic leukaemia | 14 (4.7%) | 7 (4.3%) | 7 (5.2%) | |
| Acute myeloid leukaemia | 66 (22.3%) | 34 (21.1%) | 32 (23.7%) | |
| Hodgkins disease | 14 (4.7%) | 7 (4.3%) | 7 (5.2%) | |
| Myelodysplastic syndrome | 18 (6.1%) | 8 (5.0%) | 10 (7.4%) | |
| Other | 19 (6.4%) | 7 (4.3%) | 12 (8.9%) | |
| HCT‐CI score, n (%) | 0.597 a | |||
| 0 | 63 (21.3%) | 32 (19.9%) | 31 (23.0%) | |
| 1 | 23 (7.8%) | 15 (9.3%) | 8 (5.9%) | |
| 2 | 67 (22.6%) | 40 (24.8%) | 27 (20.0%) | |
| 3 | 69 (23.3%) | 37 (23.0%) | 32 (23.7%) | |
| 4+ | 74 (25.0%) | 37 (23.0%) | 37 (27.4%) | |
| Disease risk index, n (%) | 0.940 a | |||
| Low | 67 (22.6%) | 36 (22.4%) | 31 (23.0%) | |
| Intermediate | 156 (52.7%) | 84 (52.2%) | 72 (53.3%) | |
| High/very high | 73 (24.7%) | 41 (25.5%) | 32 (23.7%) | |
| Regimen intensity | 0.798 b | |||
| Myeloablative | 209 (70.6%) | 115 (71.4%) | 94 (69.6%) | |
| Reduced intensity/non‐myeloablative | 87 (29.4%) | 46 (28.6%) | 41 (30.4%) | |
| Previous chemotherapy regimens | 3.27 ± 1.8 | 3.28 ± 1.8 | 3.25 ± 1.9 | 0.722 |
| KPS | 90.2 ± 8.1 | 90.5 ± 8.0 | 89.8 ± 8.0 | 0.447 |
| Albumin | 4.08 ± 0.4 | 4.09 ± 0.4 | 4.07 ± 0.3 | 0.702 |
| Prior HCT, n (%) | 21 (7.1%) | 11 (6.8%) | 10 (7.4%) | 1.0 b |
| FEV1 (%) | 92.0 ± 15.3 | 89.9 ± 14.8 | 94.6 ± 15.6 | 0.009 |
| DLCO | 74.5 ± 14.6 | 76.5 ± 15.6 | 72.1 ± 12.9 | 0.009 |
| COPD | 0.113 a | |||
| Stage 0 (no COPD) | 222 (75.0%) | 113 (70.2%) | 109 (80.7%) | |
| Stage 1 (mild) | 31 (10.5%) | 20 (12.4%) | 11 (8.2%) | |
| Stage 2–3 (moderate–severe) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Stage U (undefined) | 43 (14.5%) | 28 (17.4%) | 15 (11.1%) | |
| Lumbar CT Available, n (%) | 215 (72.6%) | 116 (72.0%) | 99 (73.3%) | 0.896 |
| Length of Stay | 24.0 (6) | 23 (5) | 24 (6.5) | 0.140 c |
| T4 body composition | ||||
| Skeletal muscle (cm2) | 183.9 ± 50.7 | 218.2 ± 40.0 | 142.9 ± 25.4 | <0.001 |
| Subcutaneous adipose tissue (cm2) | 212.9 ± 103.9 | 194.9 ± 93.5 | 234.3 ± 111.7 | 0.001 |
| Skeletal muscle radiodensity (HU) | 38.5 ± 6.8 | 38.9 ± 7.0 | 37.9 ± 6.6 | 0.211 |
| L3 body composition d | ||||
| Skeletal muscle (cm2) | 128.2 ± 34.7 | 152.1 ± 26.7 | 100.1 ± 18.0 | <0.001 |
| Subcutaneous adipose tissue (cm2) | 198.8 ± 103.6 | 192.4 ± 102.7 | 206.2 ± 104.5 | 0.331 |
| Visceral adipose tissue (cm2) | 131.3 ± 96.3 | 170.2 ± 100.3 | 85.8 ± 67.5 | <0.001 |
| Skeletal muscle radiodensity (HU) | 35.5 ± 7.3 | 35.9 ± 7.2 | 35.2 ± 7.4 | 0.487 |
| Sarcopenia, n (%) | 132 (61.4%) | 75 (64.7%) | 57 (57.6%) | 0.326 b |
| BMI category, n (%) | 0.005 a | |||
| Underweight | 4 (1.4%) | 1 (0.6%) | 3 (2.2%) | |
| Normal weight | 89 (30.1%) | 36 (22.4%) | 53 (39.3%) | |
| Overweight | 116 (39.2%) | 68 (42.2%) | 48 (35.6%) | |
| Obese | 87 (29.4%) | 56 (34.8%) | 31 (23.0%) | |
Variables are presented as mean ± standard deviation, or median (interquartile range). P‐values are Student's t‐tests unless otherwise specified. BMI, body mass index; COPD, chronic obstructive pulmonary disease defined by spirometry 22 ; CT, computed tomography; DLCO, diffusing capacity of the lung for carbon monoxide, adjusted for haemoglobin; FEV1, forced expiratory volume in 1 second; HCT, haematopoietic cell transplantation; HCT‐CI, haematopoietic cell transplantation‐specific co‐morbidity index; HU, Hounsfield unit; KPS, Karnofsky performance status.
χ 2 test.
Fisher's exact test.
Mann–Whitney U test.
Variables of L3 body composition, including sarcopenia prevalence, have a sample size of 215 (n = 99 female, n = 116 male).